Published in Scand J Infect Dis on January 01, 1980
Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother (1991) 1.52
Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother (1991) 1.50
Influence of four modes of administration on penetration of aztreonam, cefuroxime, and ampicillin into interstitial fluid and fibrin clots and on in vivo efficacy against Haemophilus influenzae. Antimicrob Agents Chemother (1985) 1.49
Clinical significance of antibiotic tissue penetration. Clin Pharmacokinet (1989) 1.48
Rate of methicillin penetration into normal heart valve and experimental endocarditis lesions. Antimicrob Agents Chemother (1982) 1.08
Penicillin pharmacodynamics in four experimental pneumococcal infection models. Antimicrob Agents Chemother (2001) 1.07
Concentrations of ticarcillin and clavulanic acid in human bone after prophylactic administration of 5.2 g of timentin. Antimicrob Agents Chemother (1987) 0.87
Penetration of antibiotics into the surgical wound in a canine model. Antimicrob Agents Chemother (1989) 0.81
Penetration of cefotetan into suction skin blister fluid and tissue homogenates in patients undergoing abdominal surgery. Antimicrob Agents Chemother (1994) 0.80
Fluconazole penetration into the human prostate. Antimicrob Agents Chemother (1995) 0.77
Penetration of cefoperazone into surgical wound drainage in patients undergoing head and neck surgery. Antimicrob Agents Chemother (1984) 0.75
Cephalosporin penetration into soft tissue of paralyzed limbs. Antimicrob Agents Chemother (1989) 0.75
Prophylaxis with oral cefadroxil versus intravenous cefuroxime in trochanteric fracture surgery. A clinical multicentre study. Arch Orthop Trauma Surg (1995) 0.75
Cefuroxime - a new cephalosporin antibiotic. J Antibiot (Tokyo) (1976) 7.95
GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob Agents Chemother (1980) 6.77
Variation in antibiotic use in the European Union. Lancet (2001) 6.02
Cefuroxime, a new cephalosporin antibiotic: activity in vivo. Antimicrob Agents Chemother (1976) 4.61
Antimicrobial resistance. Is a major threat to public health. BMJ (1998) 4.18
Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci (1999) 3.77
Laoratory appraisal of cephalexin. Antimicrob Agents Chemother (Bethesda) (1968) 3.75
Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother (2009) 3.62
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother (1993) 2.92
Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization? Am J Epidemiol (1982) 2.62
Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. Lancet Infect Dis (2008) 2.17
Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. Antimicrob Agents Chemother (1992) 2.14
Pharmacodynamic effects of subinhibitory concentrations of beta-lactam antibiotics in vitro. Antimicrob Agents Chemother (1991) 1.88
Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection. J Antimicrob Chemother (2003) 1.80
Inhibition of beta-lactamase decomposition of cephaloridine and cephalothin by other cephalosporins. Antimicrob Agents Chemother (Bethesda) (1966) 1.61
Treatment of brain abscess with cefotaxime and metronidazole: prospective study on 15 consecutive patients. Clin Infect Dis (1993) 1.57
Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. J Antimicrob Chemother (2009) 1.51
Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target. J Gen Virol (1988) 1.49
Control of antimicrobial resistance: time for action. The essentials of control are already well known. BMJ (1998) 1.48
A new method to determine postantibiotic effect and effects of subinhibitory antibiotic concentrations. Antimicrob Agents Chemother (1993) 1.38
Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother (2002) 1.37
In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother (1998) 1.34
In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria. Antimicrob Agents Chemother (1998) 1.31
A morphological study of experimental rabbit staphylococcal endocarditis and aortitis. I. Formation and effect of infected and uninfected vegetations on the aorta. Br J Exp Pathol (1986) 1.30
Postantibiotic and bactericidal effect of imipenem against Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis (1989) 1.29
Simultaneous comparison of three methods for assessing ceftazidime penetration into extravascular fluid. Antimicrob Agents Chemother (1982) 1.28
The use of antibiotic serum levels to predict concentrations in tissues. Scand J Infect Dis (1986) 1.27
Effects of benzylpenicillin on Streptococcus pyogenes during the postantibiotic phase in vitro. J Antimicrob Chemother (1989) 1.27
Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model. Antimicrob Agents Chemother (1996) 1.23
Tissue distribution of ampicillin: assays in muscle tissue and subcutaneous tissue cage fluid from normal and nephrectomized rabbits. Scand J Infect Dis (1981) 1.21
Major change in the use of antibiotics following a national programme: Swedish Strategic Programme for the Rational Use of Antimicrobial Agents and Surveillance of Resistance (STRAMA). Scand J Infect Dis (1999) 1.21
A microtechnique for the determination of antibiotics in muscle. J Antimicrob Chemother (1981) 1.20
Comparative acitivity of ampicillin and cefuroxime against three types of Haemophilus influenzae. Antimicrob Agents Chemother (1977) 1.19
Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother (1991) 1.19
Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother (2014) 1.14
ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. Mol Cell Neurosci (2000) 1.14
Use of IgM-hepatitis A antibody testing. Investigating a common-source, food borne outbreak. JAMA (1981) 1.13
A problem in the interpretation of beta-lactam antibiotic levels in tissues. J Antimicrob Chemother (1983) 1.12
Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens. Antimicrob Agents Chemother (2001) 1.11
Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrob Agents Chemother (1995) 1.10
Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model. Antimicrob Agents Chemother (2001) 1.09
Five versus ten days treatment of group A streptococcal pharyngotonsillitis: a randomized controlled clinical trial with phenoxymethylpenicillin and cefadroxil. Scand J Infect Dis (1988) 1.07
Penicillin pharmacodynamics in four experimental pneumococcal infection models. Antimicrob Agents Chemother (2001) 1.07
Penetration of beta-lactam antibiotics into cardiac vegetations, aorta and heart muscle in experimental Staphylococcus aureus endocarditis: comparison of ceftazidime, cefuroxime and methicillin. J Antimicrob Chemother (1985) 1.07
A morphological study of experimental staphylococcal endocarditis and aortitis. II. Inter-relationship of bacteria, vegetation and cardiovasculature in established infections. Br J Exp Pathol (1986) 1.06
Strama--a Swedish working model for containment of antibiotic resistance. Euro Surveill (2008) 1.03
Implanted cotton threads; a novel method for measuring concentrations of antibiotics in tissue fluid. J Antimicrob Chemother (1979) 1.01
Comparative pharmacokinetics of ceftazidime in fibrin clots and cardiac vegetations in rabbits with Staphylococcus aureus endocarditis. Antimicrob Agents Chemother (1985) 1.01
Near absence of vancomycin-resistant enterococci but high carriage rates of quinolone-resistant ampicillin-resistant enterococci among hospitalized patients and nonhospitalized individuals in Sweden. J Clin Microbiol (1999) 1.00
Effects of supra- and sub-MIC benzylpenicillin concentrations on group A beta-haemolytic streptococci during the postantibiotic phase in vivo. J Antimicrob Chemother (1990) 1.00
Influence of surface area/volume ratio on the kinetics of antibiotics in different tissues and tissue fluids. Scand J Infect Dis Suppl (1985) 0.99
Antibiotic tissue concentrations: methodological aspects and interpretation of results. Scand J Infect Dis Suppl (1985) 0.98
Penetration of ampicillin and dicloxacillin into tissue cage fluid in rabbits: relation to serum and tissue protein binding. Scand J Infect Dis (1981) 0.97
Therapeutic activity of ceftazidime and eleven other beta-lactam antibiotics against experimental Haemophilus influenzae, type b meningitis. J Antimicrob Chemother (1984) 0.96
Experimental staphylococcal endocarditis and aortitis. Morphology of the initial colonization. Virchows Arch A Pathol Anat Histopathol (1986) 0.96
An in vivo model for evaluation of the postantibiotic effect. Scand J Infect Dis (1988) 0.96
Throat carrier rates of beta-hemolytic streptococci among healthy adults and children. Scand J Infect Dis (1988) 0.94
Penetration of cefotaxime and desacetylcefotaxime into brain abscesses in humans. Antimicrob Agents Chemother (1991) 0.91
Comparison of ceftazidime, cefuroxime and methicillin in the treatment of Staphylococcus aureus endocarditis in rabbits. J Antimicrob Chemother (1984) 0.90
In-vitro activity of azithromycin in against intracellular Helicobacter pylori. J Antimicrob Chemother (1996) 0.89
Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation. Clin Microbiol Infect (2002) 0.89
Pharmacodynamic effects of subinhibitory antibiotic concentrations. Scand J Infect Dis Suppl (1990) 0.87
Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase. Antimicrob Agents Chemother (1997) 0.87
Evaluation of ceftazidime in experimental Klebsiella pneumoniae pneumonia: comparison with other antibiotics and measurement of its penetration into respiratory tissues and secretions. J Antimicrob Chemother (1986) 0.87
New immunofluorescence method for the identification of group a, b, c, e, and g streptococci. Acta Pathol Microbiol Scand B (1975) 0.86
Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Response Mod (1986) 0.85
Implanted tissue-cages: a critical evaluation of their relevance in measuring tissue concentrations of antibiotics. Scand J Infect Dis Suppl (1978) 0.85
Importance of drug-protein interactions and protein concentrations for antibiotic levels in serum and tissue fluid. Scand J Infect Dis Suppl (1985) 0.84
Antibiotic prescription practices, consumption and bacterial resistance in a cross section of Swedish intensive care units. Acta Anaesthesiol Scand (2002) 0.83
Personnel costs and preparation time in a centralized intravenous admixture program. Am J Hosp Pharm (1986) 0.83
Susceptibility of Chlamydia pneumoniae to azithromycin and doxycycline: methodological aspects on the determination of minimal inhibitory and minimal bactericidal concentrations. Scand J Infect Dis (1997) 0.83
Low antibiotic resistance rates in Staphylococcus aureus, Escherichia coli and Klebsiella spp but not in Enterobacter spp and Pseudomonas aeruginosa: a prospective observational study in 14 Swedish ICUs over a 5-year period. Acta Anaesthesiol Scand (2007) 0.83
In vitro studies of the pharmacodynamics of teicoplanin against Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium. Clin Microbiol Infect (2003) 0.83
A new in-vitro kinetic model to study the pharmacodynamics of antifungal agents: inhibition of the fungicidal activity of amphotericin B against Candida albicans by voriconazole. Clin Microbiol Infect (2007) 0.82
Antibiotic tissue levels: are tissue cages relevant for their measurement? J Antimicrob Chemother (1979) 0.82
Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis (2010) 0.82
Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model. J Antimicrob Chemother (2005) 0.82
Ampicillin-resistant enterococci in a Swedish university hospital: nosocomial spread and risk factors for infection. Scand J Infect Dis (2001) 0.82
Concentrations of phenoxymethylpenicillin and cefadroxil in tonsillar tissue and tonsillar surface fluid. Eur J Clin Microbiol (1987) 0.82
Randomized comparison of aztreonam and cefuroxime in gram-negative upper urinary tract infections. Infection (1990) 0.82
First documented case of human babesiosis in Sweden. Scand J Infect Dis (1992) 0.81
The influence of protein binding on the antibacterial activity of faropenem against Haemophilus influenzae. Clin Microbiol Infect (2004) 0.81
Evaluation of ceftazidime, ampicillin and chloramphenicol in experimental Haemophilus influenzae type b meningitis. J Antimicrob Chemother (1984) 0.81
Assay of antibiotic susceptibility of Chlamydia pneumoniae. Scand J Infect Dis Suppl (1997) 0.81
Comparative penetration of ceftazidime into cardiac and skeletal muscle in rabbits. Chemotherapy (1986) 0.80
Effect of antibiotic protein binding on the killing rate of Staphylococcus aureus and on the paradoxical phenomenon. Chemotherapy (1987) 0.80
In vitro activity of cefuroxime against Treponema pallidum and Neisseria gonorrhoeae. J Antimicrob Chemother (1980) 0.80
In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (Telithromycin) against Chlamydia pneumoniae. Antimicrob Agents Chemother (2000) 0.80
Bacterial filamentation and in vivo efficacy: a comparison of several cephalosporins. J Antimicrob Chemother (1981) 0.80
Paradoxical effects of antibiotics. Scand J Infect Dis Suppl (1990) 0.80
Pharmacokinetics of intravenous cefuroxime during intermittent and continuous arteriovenous hemofiltration. Clin Nephrol (1988) 0.79
In vitro pharmacodynamic studies of activities of ketolides HMR 3647 (Telithromycin) and HMR 3004 against extracellular or intracellular Helicobacter pylori. Antimicrob Agents Chemother (2001) 0.79
A freeze-fracture study of the anterior and posterior latissimus dorsi muscle of the chicken. Anat Rec (1980) 0.79
Tissue penetration of ampicillin: parallel determinations of levels in tissue cage fluid and rabbit muscle. J Antimicrob Chemother (1980) 0.77
Annual reports of antibiotic use and resistance--for whom? Neth J Med (2004) 0.77
Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration. J Antimicrob Chemother (1990) 0.77
Concentrations of doxycycline in muscle tissue and muscle tissue fluid. Scand J Infect Dis Suppl (1988) 0.77